This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Acute promyelocytic leukaemia

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Acute promyelocytic leukaemia (APL) is a distinct subtype of AML which is characterised by the presence of many promyelocytes in peripheral blood and marrow aspirate.

Promyelocytes are:

  • cells with a granular cytoplasm which stains brown with myeloperoxidase
  • normally precursors of neutrophils, basophils, eosinophils and monocytes

APL accounts for approximately 5-15% of acute myeloid leukaemia (1).

The following are considered independent risk factors for the development of APL in a patient with AML:

  • younger age
  • Hispanic background
  • obesity (1)

The major cause of mortality is bleeding, particularly intracranial, which may be exacerbated by chemotherapy.

Although relatively rare, APL is important since it is the first cancer in which a specific treatment has been developed which targets the genetic defect responsible for tumorigenesis.


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page